EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Tagraxofusp in myeloid malignancies

Antonella Bruzzese iD, Enrica Antonia Martino, Caterina Labanca, Francesco Mendicino iD, Eugenio Lucia, Virginia Olivito, Antonino Neri, Annalisa Imovilli, Fortunato Morabito, Ernesto Vigna, Massimo Gentile iD

Hematological Oncology · 2024

DOI: 10.1002/hon.3234 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematological Oncology, 2024. Verfasst von Antonella Bruzzese und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Skin Neoplasms, Hematologic Neoplasms, Recombinant Fusion Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tagraxofusp (or SL‐401) is a recombinant molecule composed of human interleukin‐3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). Tagraxofusp's most significant success has come from studies involving patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive disease that is usually refractory to conventional chemotherapy. Tagraxofusp had an acceptable safety profile and high efficacy in early phase I/II studies on patients with BPDCN. Another phase II study confirmed the good response rates, resulting in Food and Drugs Administration and European Medicine Agency approval of tagraxofusp for the treatment of BPDCN. Considering its high efficacy and its manageable safety profile, tagraxofusp has been suddenly explored in other myeloid malignancies with high expression of cell surface CD123, both in monotherapy or combination strategies. The triplet tagraxofusp‐azacytidine‐venetoclax appears to be of particular interest among these combinations. Furthermore, combination strategies may be used to overcome tagraxofusp resistance. The downregulation of DPH1 (diphthamide biosynthesis 1), the enzyme responsible for the conversion of histidine 715 on eEF2 to diphthamide, which is then the direct target of ADP ribosylation DT, is typically associated with this resistance phenomenon. It has been discovered that azacitidine can reverse DHP1 expression and restore sensitivity to tagraxofusp. In conclusion, the success of tagraxofusp in BPDCN paved the way for its application even in other CD123‐positive malignancies. Nowadays, several ongoing trials are exploring the use of tagraxofusp in different myeloid neoplasms. This review aims to summarize the actual role of tagraxofusp in BPDCN and other CD123‐positive myeloid malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersSkin NeoplasmsHematologic NeoplasmsRecombinant Fusion ProteinsHumansInterleukin-3 Receptor alpha SubunitDendritic CellsAzacitidineAcute DiseaseClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

AMLBPDCNCD123myeloid malignanciestagraxofusp

Substanzen

tagraxofuspInterleukin-3 Receptor alpha SubunitAzacitidineRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
  • Scientific Directorate IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Hematology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy.
  • Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

ORCID-Profile: Antonella Bruzzese, Francesco Mendicino, Massimo Gentile

Zitieren

APA

Bruzzese, A., Martino, E. A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Neri, A., Imovilli, A., Morabito, F., Vigna, E., & Gentile, M. (2024). Tagraxofusp in myeloid malignancies. Hematological Oncology. https://doi.org/10.1002/hon.3234

Vancouver

Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, et al. Tagraxofusp in myeloid malignancies. Hematological Oncology. 2024. doi:10.1002/hon.3234

BibTeX
@article{Bruzzese2024,
  author = {Bruzzese, Antonella and Martino, Enrica Antonia and Labanca, Caterina and Mendicino, Francesco and Lucia, Eugenio and Olivito, Virginia and Neri, Antonino and Imovilli, Annalisa and Morabito, Fortunato and Vigna, Ernesto and Gentile, Massimo},
  title = {Tagraxofusp in myeloid malignancies},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3234}
}
Kostenlos starten →